Consolidated Non-Financial Information Statement and Sustainability Information

The report presents Pharma Mar's 2024 consolidated sustainability information under ESRS and describes a double materiality assessment covering impacts, risks and opportunities across the value chain. It reports SBTi-validated targets to reduce Scope 1 and 2 emissions by 42% by 2030 and achieve a long-term net-zero target by 2050. Renewable energy represented 45.4% of total energy consumption, while total energy consumption was 11,277 MWh. The company also reports EUR 103.5 million of R&D investment, mainly supporting ongoing clinical development.